Also known as Ala-Asp-Glu-Leu · ADEL tetrapeptide
Synthetic Ala-Asp-Glu-Leu tetrapeptide studied as a respiratory-tissue bioregulator.
Bronchogen is a synthetic tetrapeptide (Ala-Asp-Glu-Leu) in the Khavinson short-peptide bioregulator series, studied for effects on bronchial and respiratory-tract tissue.
Bronchogen (Ala-Asp-Glu-Leu) is the respiratory-directed member of the defined short-peptide bioregulator family, studied in the context of chronic bronchopulmonary conditions in the originating research tradition.
Reported work examined bronchial epithelial markers and inflammatory indices in respiratory models, consistent with the class hypothesis of tissue-selective transcriptional modulation. Evidence is concentrated in one research tradition with limited independent replication, and it is not FDA-approved.
Proposed gene-regulatory modulation of bronchial epithelial gene expression.
Behind every vial of Bronchogen is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Bronchogen, specifically, is brought into being.
On paper, Bronchogen weighs in at roughly 446.5 daltons. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling Bronchogen means roughly 4 coupling cycles on the synthesizer — one protected residue added at a time, which is also 4 chances for an incomplete coupling to seed a deletion impurity. It is a short sequence, which makes the build comparatively tractable — but short does not mean trivial, and purity is still won or lost downstream.
The crude mixture — Bronchogen plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Bronchogen proves itself: identity confirmed by mass spectrometry against its ~446.5 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Bronchogen — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Bronchogen to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Bronchogen, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Bronchogen is a synthetic Ala-Asp-Glu-Leu tetrapeptide studied as a respiratory-tissue bioregulator in the Khavinson short-peptide series.
The bronchi and respiratory-tract epithelium — each bioregulator in the series is framed around a specific target tissue.
It is concentrated in a single research tradition and is largely preclinical, so findings are preliminary. This page is a research and educational reference.
Synthetic tetrapeptide investigated for telomerase activity and circadian effects.
ViewThymus-derived polypeptide complex — the founding tissue bioregulator (Cytomax) studied for immune restoration.
ViewSynthetic Lys-Glu dipeptide — the defined short-peptide successor to Thymalin, studied for immune and aging endpoints.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.